VIFOR-PHARMA
5.5.2020 13:03:14 CEST | Business Wire | Press release
Regulatory News:
Vifor Pharma announced that its partner, Akebia Therapeutics, Inc ., today reported positive top-line results from INNO2 VATE, Akebia’s global phase-III cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anaemia due to Chronic Kidney Disease (CKD) in adult dialysis-dependent patients (DD-CKD). Upon successful completion of its phase-III program, which includes Akebia’s studies of vadadustat for the treatment of anemia due to CKD in non-dialysis patients, Akebia plans to submit a New Drug Application (NDA) for vadadustat for the treatment of anemia due to CKD in dialysis dependent and non-dialysis dependent patients, to the U.S. Food and Drug Administration (FDA).
“We are delighted with the positive top-line data from Akebia’s INNO2 VATE global phase-III global study of vadadustat for the treatment of anemia due to CKD in dialysis patients,” comments Stefan Schulze, Vifor Pharma President of the Executive Committee and Chief Operating Officer, “By successfully meeting its primary efficacy and cardiovascular endpoints, we believe the INNO2 VATE data positions vadadustat as a potential new oral standard of care for treating all populations of dialysis patients, including both incident and prevalent dialysis patients with anemia due to CKD, subject to its approval. We look forward to working with Akebia to bring vadadustat, upon approval, to our dialysis patients.”
Vifor Pharma was granted an exclusive license to sell vadadustat to Fresenius Kidney Care dialysis centers and to specific third party dialysis organisations that together account for approximately 60% of the dialysis patients in the US, subject to approval of vadadustat by the FDA and its inclusion in Medicare’s bundled reimbursement model for dialysis, or reimbursement using the Transitional Drug Add-On Payment Adjustment (TDAPA), and a milestone payment by Vifor Pharma.
About Akebia’s Global phase-III INNO2 VATE Program
Akebia’s public announcement highlighted that its global INNO2 VATE program is a cardiovascular outcomes program which includes two separate phase-III studies (Correction/Conversion and Conversion ) and which collectively enrolled 3,923 dialysis-dependent patients with anemia due to chronic kidney disease (CKD). Both INNO2 VATE studies are global, multicenter, open label (sponsor blinded), active-control (darbepoetin alfa- an injectable erythropoiesis stimulating agent (ESA)), non-inferiority studies. According to Akebia’s announcement: “Vadadustat achieved the primary and key secondary efficacy endpoint in each of the two INNO2 VATE studies, demonstrating non-inferiority to darbepoetin alfa as measured by a mean change in hemoglobin (Hb) between baseline and the primary evaluation period (weeks 24 to 36) and secondary evaluation period (weeks 40 to 52). Vadadustat also achieved the primary safety endpoint of the INNO2 VATE program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE), which is a composite of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke across both INNO2 VATE studies. Each analysis was measured against non-inferiority (NI) margins agreed upon with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).”
About Vadadustat
Vadadustat is Akebia’s oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 development for the treatment of anemia due to CKD. Vadadustat is designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is an investigational therapy and is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.
Please visit https://akebia.com/pr-552020/ to access the complete public announcement from Akebia Therapeutics, which does not form a part of this release.
Vifor Pharma Group is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005517/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brown Brothers Harriman Investor Services and SimCorp Forge Strategic Alliance to Provide Integrated End-to-End Technology, Data, and Services Solution for Global Asset Managers28.1.2026 15:00:00 CET | Press release
New offering leverages BBH Infomediary® to combine the benefits of the SimCorp One enterprise platform, including SimCorp Managed Business Services, with BBH Investor Services’ fund servicing and custody product suite. BBH Infomediary used to integrate BBH and SimCorp’s platforms and to connect to third parties in a unique open architecture model. Addresses the needs of global asset managers seeking to streamline and modernize their operating model. Quoniam Asset Management, a leading systematic manager, is the first to benefit from this data-driven offering. Brown Brothers Harriman (BBH), a privately held global financial services firm, and SimCorp, a leading global financial technology company, today announced a new strategic alliance to address the needs of global asset managers requiring an integrated, end-to-end technology, data, and services solution. Enhancing both firms’ existing offerings, this solution uses BBH Infomediary to integrate SimCorp One’s front and middle office ca
Wunderkind Joins Klaviyo Marketplace, Bringing Identity-Based Personalization and Revenue Growth to E-Commerce Brands28.1.2026 15:00:00 CET | Press release
New integration unlocks greater site identification, real-time personalization, and scalable triggered messaging Wunderkind, the AI decisioning platform that delivers identity resolution and cross-channel personalization to scale performance and reach, today announced its official debut on the Klaviyo App Marketplace. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128210560/en/ The integration brings Wunderkind’s identity insights directly into Klaviyo’s B2C CRM, powering real-time profiles, segments, and flows that help brands recognize more customers earlier in the journey and deliver relevant experiences across email, SMS and other Klaviyo-powered channels. By layering Wunderkind’s industry-leading Identity Network — built on more than 9 billion device profiles and over a billion unique user identities — into Klaviyo’s unified customer profile, marketers can strengthen their understanding of who customers are, unify id
Geoprofessionals Spend a Quarter of Their Time Managing Data and Are Increasingly Turning to AI, Reveals New Seequent Survey28.1.2026 15:00:00 CET | Press release
Mining and civil geoprofessionals rate data management as highly/critically important but face big challenges unlocking value from complex datasets Seequent, the Bentley Subsurface company, says mining and civil geoprofessionals turning to AI still struggle to unlock value from increasingly complex, multisource datasets, according to its 7th Geoprofessionals Data Management Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128879634/en/ Geoprofessionals spend a quarter of their time managing data and are increasingly turning to AI, reveals new Seequent survey. The global report, based on a survey of more than 1,000 geoprofessionals worldwide, highlights teams grappling with complex datasets across multiple software platforms, unmanaged historical data, and significant time spent on routine data administration. Angela Harvey, Chief Customer Officer, Seequent, said: ‘According to the report findings, geoprofessionals o
WeFi Technology Group Announces Partnership with PGA Tour Rising Star28.1.2026 14:40:00 CET | Press release
Shared values of vision, competitiveness, and ambition underscore multi-year partnership with the 2025 PGA Rookie of the Year. WeFi Technology Group, a global provider of technology-enabled working capital solutions, today announced a multi-year brand partnership with Aldrich Potgieter, the 2025 PGA Tour Rookie of the Year and one of the most promising young players on the international golf circuit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128340648/en/ Aldrich Potgieter, 2025 PGA Tour Rookie of the Year and one of the most promising young players on the international golf circuit. Leveraging its AI-powered platform, WeFi Technology operates at the intersection of finance, technology, and innovation in over 40 countries around the globe, delivering working capital solutions that drive client growth. Potgieter rose to global prominence at just 19 years old when he became the youngest winner in Korn Ferry Tour histor
CSG Announces Contract Renewal with DISH Network28.1.2026 14:30:00 CET | Press release
Drives seamless customer experiences and operational agility through 2030. CSG® (NASDAQ: CSGS) today announced a multi-year contract extension with DISH Network to continue powering best-in-class customer service. For 45 years, DISH has been connecting communities across the nation, evolving from a satellite pioneer into a diverse connectivity leader. CSG has been a trusted business enabler for much of that journey and will continue to help DISH support its customers through 2030. “CSG has been instrumental to how DISH serves customers,” said John Swieringa, President, Technology, and Chief Operating Officer, DISH. “Our collaboration with CSG will continue to bring us the flexibility and speed we need to deliver the exceptional experiences our customers deserve.” For three decades, DISH has trusted CSG to manage billing and payment services for millions of subscribers with accuracy and reliability. With CSG’s leading SaaS platform for billing, customer care, and business optimization,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom